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LETTERS
The case we describe is consistent 
with the cutaneous variant of 
melioidosis. However, the patient’s 
initial general symptoms (probably 
attenuated by early treatment with 
antimicrobial drugs) could have 
indicated a transitory, disseminated 
phase of disease such as that 
experienced by 4 (all adults) of the 58 
cases of primary cutaneous melioidosis 
in the Australian study (9). It is not 
known whether B. pseudomallei 
was transmitted to the patient by an 
airborne route or percutaneously as 
in most cases (i.e., wounds infected 
by contaminated water or mud); other 
transmission modes are anecdotal 
(1–5). Moreover, our patient had none 
of the classic risk factors, although 
dengue fever as an underlying co-
infection has been described (10).
The patient was treated with 
intravenous ceftazidime and oral 
cotrimoxazole at the minimum 
treatment duration recommended for 
melioidosis (1–5). Purely cutaneous 
variants of melioidosis may be treated 
exclusively by oral cotrimoxazole 
over 12 weeks (9), but we opted 
to prescribe initial intravenous 
treatment because of her general 
symptoms. We stopped follow-up 
11 weeks after the treatment period 
ended because of persisting illness 
remission, but lifelong monitoring is 
recommended for adult patients (1,4) 
because relapses occur in ≈10% of 
adult patients despite well-conducted 
antimicrobial drug treatment (3,4).
In conclusion, melioidosis as a 
potential emerging infectious disease 
should be considered in cases of 
isolated skin lesions as well as in cases 
of unexplained fever with nonspeciﬁ  c 
symptoms. Furthermore, the disease 
should be considered not only among 
travelers returning from known 
disease-endemic regions but also in 
those coming from the Caribbean. 
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To the Editor: We read with 
interest the article by Baddley 
et al. (1) and appreciate their 
efforts to characterize incidence 
rates of mycoses. We agree that 
histoplasmosis, blastomycosis, and 
coccidioidomycosis are differential 
diagnoses for patients with consistent 
symptoms but who reside outside 
mycosis-endemic areas.
However, we believe that the 
methods of Baddley et al. probably 
do not determine the true incidence of 
these mycoses in sparsely populated 
states such as Arkansas. Their estimates 
contrast markedly with surveillance 
data from the Arkansas Department 
of Health (Table) and with our clinical 
experience as infectious disease 
physicians. We characterize Arkansas 
as a state in which histoplasmosis and 
blastomycosis incidence is high and 
coccidioidomycosis incidence is low; 
however, Baddley et al. indicate that in 
Arkansas, incidence of blastomycosis 
is relatively low and incidence of 
coccidioidomycosis is high.
To investigate whether this 
ﬁ   nding might be associated with 
their small 5% sample of Medicare 
beneﬁ  ciaries, we used data from the 
Arkansas census to determine that 
in 2008 the population of adults 
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>65 years of age was ≈407,014, 
and during 1999–2008, there were 
≈3,840,896 person-years for persons 
in this age group. A 5% sample 
would account for ≈192,045 person-
years. Using their rate ranges (7.84–
12.3 cases/100,000 person-years 
for histoplasmosis, 3.97–6.71 for 
coccidioidomycosis, and 0.39–0.86 
for blastomycosis), we calculated 
the approximate numbers of cases in 
their sample: 15–23 histoplasmosis 
cases, 7–12 coccidioidomycosis 
cases, and only 1 blastomycosis 
case. Compared with rates from 
surveillance averaged over the 10 
years, the midpoints of the Baddley 
et al. estimates are ≈6-fold higher for 
histoplasmosis,  ≈60-fold higher for 
coccidioidomycosis, and ≈0.4-fold 
lower for blastomycosis. Only their 
estimate for blastomycosis incidence 
falls within the 10-year 95% CIs 
from surveillance data. We believe 
that the small cell sizes require that 
the rate estimates of Baddley et al. be 
interpreted with care, especially with 
respect to less populous states.
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In Response: We thank Haselow 
et al. (1) for their careful review of 
our article (2). They raise the relevant 
concern about potential instability of 
incidence rates from our data because 
of small cell sizes. We agree that 
use of administrative data has major 
limitations. As such, our intent was 
not to compare infection incidences 
of individual states; but rather, our 
intent was to focus on geographic 
distribution of endemic mycoses and 
whether infections occurred in non–
mycosis-endemic areas.
Speciﬁ   cally, for blastomycosis, 
our study showed incidence in 
Arkansas to be 0.8 (0.12–5.8) cases 
per 100,000 person-years, comparable 
to the rate provided by Haselow et 
al. of 1.1 case per 100,000 person-
years (1). For coccidioidomycosis, 
our study found the rate to be much 
higher than that calculated from the 
Arkansas surveillance data. Potential 
reasons for this discrepancy might be 
lack of case capture with surveillance 
data, because mandatory reporting for 
coccidioidomycosis is not required 
in Arkansas, or misclassiﬁ  cation  of 
incident cases in the administrative 
data. Finally, for histoplasmosis, 
the incidence rate calculated from 
administrative data was much higher 
than that reported by Haselow et al. 
By using administrative data, we 
identiﬁ   ed a large number (15) of 
cases and doubt that rate instability 
is present. We agree that surveillance 
that uses administrative data has 
inherent limitations, which require 
that care be taken when interpreting 
epidemiologic measures, especially 
when sample sizes are small.
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Table. Reported cases of fungal diseases in Arkansas, by year* 
Disease
No. cases/no. cases in persons >65 y of age  Incidence rate (95% CI)† 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008  Overall    Persons  >65  y 
Blastomycosis,  
n = 166/43 
20/5 15/3 20/9 15/3 19/6 17/4 16/6 13/3 15/1 16/3    4.3  (2.9–5.7)  1.1  (0–2.3) 
Coccidioidomycosis, 
n = 3/0 
2/0  0 0 0 0  1/0  0 0 0 0    0.08  (0–0.4)  0 
Histoplasmosis,  
n = 372/65 
15/3 13/3 23/6 22/2 16/4 42/9 51/9 66/4  78/13 46/12  9.6  (0–20)  1.7  (0–3.5) 
*Data from Arkansas Department of Health. 
†No. cases/100,000 person-years, 1999–2008. 